• Save
Dr. Jeffrey Scott
Upcoming SlideShare
Loading in...5
×
 

Dr. Jeffrey Scott

on

  • 1,037 views

 

Statistics

Views

Total Views
1,037
Views on SlideShare
1,037
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Dr. Jeffrey Scott Dr. Jeffrey Scott Presentation Transcript

  • A Question of Adoption: Strategies and Best Practice for Adoption of Medical Technology
    How to maximize medical technology adoption by involving the right people at the right time throughout the product development process
    Jeffrey R. Scott, Ph.D.
    Principal Scientist
    Preclinical Affairs
    C.R. Bard, Inc. (Davol)
    jeffrey.scott@crbard.com
  • Background
    • B.Sc. Honors Life Science
    McMaster University, Canada
    • Ph.D. Medical Biophysics (Vascular Biology)
    University of Western Ontario, Canada
    • Post-Doc Surgery / Immunology
    Harvard Medical School, Boston, MA
    • Industry Preclinical Affairs
    C.R. Bard, Inc. (Davol), Warwick, RI
  • Agenda
    • Brief History of C.R. Bard, Inc. (Davol)
    • Area of Business/Research Focus
    • Rapid Innovation / Adoption
    • Surgeon Involvement During Product Development
    • The Benefits of Early Involvement
  • Who is C.R. Bard, Inc. ?
    • C.R. Bard, Inc. was founded in 1907 by Charles Russell Bard
    • A publicly traded company – BCR
    • Market Cap: $9.3B, Annual Revenue of $2.8B
    • 11,700 employees worldwide
    • Headquartered in Murray Hill, NJ
    • 5 divisions - RI, Massachusetts, Georgia, Utah, Arizona
    • Vascular, Urology, Oncology, Surgical Specialties
    • Global presence
    Europe, Japan, Canada, Australia, Latin America, Asia, China
  • Davol, Inc. History
    Joseph Davol
    Charles Davol
  • Davol, Inc. History
    1874: Davol Rubber Company founded to produce rubber medical and surgical supplies such as hot water bottles and catheters.
    1923: C. R. Bard, Inc. is exclusive Davol Foley catheter distributor
    1968: Davol, Inc. acquired by International Paper, Inc.
    1971: Davol, Inc. headquarters moved from Providence to Cranston, RI.
    1980: Acquired by C. R. Bard, Inc. from International Paper, Inc. for $48MM. Single largest selling product was the Foley catheter manufactured by Davol, Inc.
    2008: Company moved from Cranston, RI to new division headquarters in Warwick, RI.
  • C.R. Bard, Inc. (Davol) Today
    Worldwide Leader in a $600M Hernia Repair Market
    • Provide innovative solutions to surgeons
    • Broadest/deepest product line in the industry
    • Portfolio of patented, proprietary products
    • Highly trained, professional sales team - surgeon consultants
    • Innovative Marketing Programs
    • Surgeon training
    • Patient education and awareness
  • Agenda
    • Brief History of C.R. Bard, Inc. (Davol)
    • Area of Business/Research Focus
    • Rapid Innovation / Adoption
    • Surgeon InvolvementDuring Product Development
    • The Benefits of Early Involvement
  • Soft Tissue Reconstruction – Hernia Repair
  • Soft Tissue Reconstruction – Hernia Repair
  • Soft Tissue Reconstruction – Breast Reconstruction
  • Agenda
    • Brief History of C.R. Bard, Inc. (Davol)
    • Area of Business/Research Focus
    • Rapid Innovation / Adoption
    • Surgeon InvolvementDuring Product Development
    • The Benefits of Early Involvement
  • Evolution of Ventral Hernia Mesh Repair
    Tissue to Tissue Repair
    LeBlanc – First Lap ePTFE Implant 5
    Usher – First Marlex MeshRepair 1
    Bauer – First ePTFE Implant 4
    Bard Composix™ Kugel™ (CK)
    ePTFE Invented – W. L. Gore
    Rives-Stoppa Techniques 2, 3
    Bard Composix™ E/X
    Bard Composix™ L/P
    Bard Composix™
    Bard Ventralex™
    Bard Ventrio™
    Bard Dulex ™
    1993
    1997
    1987
    2001
    1969
    1976
    1958
    2003
    2006
    2008
    50%
    Emergence of Laparoscopy
    Rate of Hernia Recurrence
    < 10%
  • Synthetic Inguinal Products
    3DMax™ Mesh
    PerFix™Plug
    Bard® Soft Mesh
    MK™Patch
    Kugel™Patch
  • Synthetic Ventral & Specialty Products
    Composix™ EX Mesh
    Ventralex™ Patch
    Ventrio™ Patch
    CruraSoft™ Hiatal Patch
    Composix™ L/P Mesh
    Sepramesh™ IP
    CK™ Parastomal Patch
  • Mesh Fixation
    SorbaFix™ Absorbable Fixation Device
    PermaSorb™ Absorbable Fixation Device
  • Biologically-derived Implants
    CollaMend™ FM Implant
    AlloMax™ Surgical Graft
    XenMatrix™ Surgical Graft
  • Agenda
    • Brief History of C.R. Bard, Inc. (Davol)
    • Area of Business/Research Focus
    • Rapid Innovation / Adoption
    • Surgeon InvolvementDuring Product Development
    • The Benefits of Early Involvement
  • Product Development Process:
    The Value of Surgeon Involvement
    Product
    Launch
    Tech Dev
    Concept
    Feasibility
    Development
    New Ideas – Technique/Use
    Clinically Relevant Problems
    O.R. Interaction
    User Needs
    Focus Groups
    Marketing Research
    Concept Selection
    Pilot Study Interaction
    Design Validation
    Product Interactions
    Pivotal Study Interaction
    Message Refinement
    Design Validation
    Scientific Communication
    Podium Presence
    Surgeon Education
  • Where does innovation happen?
    Office
  • Where does innovation happen?
    Lab
  • Where does innovation happen?
    O.R.
  • Where does innovation happen?
    What is the impact on adoption?
    Office
    O.R.
    Lab
    Better Products & Rapid Adoption
  • Animal Models Developed
    in vivo: Open / Laparoscopic Ventral Hernia Repair
    Rat:Long-term Material Characterization / Adhesion Assessment / Infection
    Rabbit: Mid-term Material Characterization / Adhesion Assessment / Infection
    Pig: Short-term (Clinically-Relevant) Material / Adhesion Assessment
    Mini-Pig: Long-term (Clinically-Relevant) Material / Adhesion Assessment
    ex vivo: Hernia Repair Assessment
    PAW: Mechanical Assessment: Fixation, Burst; Laparoscopic Insertion
  • Animal Models Developed - Laparoscopic
  • Animal Models Developed - Open
  • Animal Models Developed – Breast Reconstruction
  • Agenda
    • Brief History of C.R. Bard, Inc. (Davol)
    • Area of Business/Research Focus
    • Rapid Innovation
    • Surgeon InvolvementDuring Product Development
    • The Benefits of Early Involvement
  • Surgeon Involvement - Primary Benefits
    • User Needs are Addressed in Your Products
    • Products are Safer and More Effective
    • Maximize Return on Research Investment
    • Strong Podium Presence at Launch
    • Surgeon Education
    Rapid Product Adoption
  • A Question of Adoption: Strategies and Best Practice for Adoption of Medical Technology
    How to maximize medical technology adoption by involving the right people throughout the product development process
    Jeffrey R. Scott, Ph.D.
    Principal Scientist
    Preclinical Affairs
    C.R. Bard, Inc. (Davol)
    jeffrey.scott@crbard.com